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Parasympathetic paragangliomas (PGLs) represent
neuroendocrine tumors arising from chief cells in
branchiomeric and intravagal paraganglia, which
share several histological features with their sympa-
thetic counterpart sympathoadrenal paragangliomas.
In recent years, genetic analyses of the familial form
of PGL have attracted considerable interest. However,
the majority of paragangliomas occurs sporadically
and it remains to be determined whether the patho-
genesis of sporadic paraganglioma resembles that of
the familial form. Furthermore, data on comparative
genetic aberrations are scarce. To provide fundamen-
tal cytogenetic data on sporadic and hereditary PGLs,
we performed comparative genomic hybridization us-
ing directly fluorochrome-conjugated DNA extracted
from 12 frozen and 4 paraffin-embedded tumors. The
comparative genomic hybridization data were ex-
tended by loss of heterozygosity analysis of chromo-
some 11q. DNA copy number changes were found in
10 (63%) of 16 tumors. The most frequent chromo-
somal imbalance involved loss of chromosome 11. Six
of seven familial tumors and two of nine sporadic
tumors showed loss of 11q (86% versus 22%, P 5
0.012). Deletions of 11p and 5p were found in two of
nine sporadic tumors. We conclude that overall DNA
copy number changes are infrequent in PGLs com-
pared to sympathetic paragangliomas and that loss of
chromosome 11 may be an important event in their
tumorigenesis, particularly in familial paraganglio-
mas. (Am J Pathol 2001, 158:1937–1942)
Parasympathetic paragangliomas (PGLs) are rare, highly
vascularized tumors, originating from neural crest-de-
rived chief cells of paraganglia in the head and neck
region. They share many histological features with sym-
pathoadrenal PGLs, including pheochromocytomas
(PCCs). Metastases of PGLs are uncommon, but may
emerge in lymph nodes, lung, and liver. Dependent on
the anatomical location the tumor can cause serious
symptoms like dysphagia, bradycardia, and hearing loss.
Because of this and in view of the risk of progression to
malignancy, surgical resection of PGLs is often required.
The carotid body and jugulotympanic paraganglia are
the most common sites of origin of parasympathetic
PGLs, followed by vagal, laryngeal, and aorticopulmo-
nary paraganglia.1,2 Although most parasympathetic
PGLs occur sporadically, there is a positive family history
in a considerable minority (10 to 50%) of cases.3 Predom-
inance in females, multiple PGLs, and young age of onset
are characteristic of familial PGLs, but such features have
also been reported in sporadic cases.4,5 Co-occurrence
of parasympathetic PGLs and PCCs, and occurrence in
Carney’s syndrome and neurofibromatosis type 1 have
been described.6–9 Flow cytometric analyses revealed
DNA aneuploidy in 21 to 50% of parasympathetic PGLs,
which did not predict malignant behavior or decreased
survival.10–12 A few immunohistochemical studies have
suggested a paracrine/autocrine role for IGF-II, c-myc,
bcl-2, and c-jun in PGL pathogenesis.13–15
In attempts to clarify the genetic mechanisms under-
lying the development of parasympathetic PGLs, the in-
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herited form of this tumor has so far been the main
subject of investigation. Linkage analysis and loss of
heterozygosity (LOH) studies in unrelated families pro-
vided evidence for the existence of two distinct PGL
susceptibility genes. The putative PGL1 gene (11q23)
and the PGL2 gene (11q13.1) are both thought to be
tumor suppressor genes and maternally imprinted.16–20
Recently, a third, not maternally imprinted gene was
demonstrated to cause PGL in a German family
(PGL3).21
Although substantial progress has thus been made in
the identification of genetic changes involved in the de-
velopment of hereditary PGL, comparative data on
genomic changes in sporadic and familial parasympa-
thetic PGLs are not available and it remains to be clarified
whether these tumors develop along the same genetic
pathways. To characterize cytogenetic alterations, we
investigated nine sporadic and seven familial parasym-
pathetic PGLs by comparative genomic hybridization
(CGH) analysis. In addition, LOH analysis was performed
to confirm CGH results.
Materials and Methods
Patients and Tumor Samples
Sixteen benign tumors from 14 patients with parasympa-
thetic PGLs, diagnosed between 1992 and 1996, were
studied. The average age of the patients (nine female) at
first presentation was 37 years (range, 29 to 55 years)
and the mean size of the tumors was 2.5 6 1.2 cm.
Information on family history and other tumors or relevant
conditions was obtained by reviewing medical charts and
by interviewing all patients, after an average follow-up
period of 7.8 years (94 months). Six of 14 patients had a
positive family history for parasympathetic PGL and eight
patients had sporadic PGL. A PGL was considered spo-
radic when there were no first or second degree relatives
known with a parasympathetic PGL. Clinical data are
summarized in Table 1.
DNA Extraction
Genomic DNA from 12 frozen tumors was isolated using
the D-5000 Puregene DNA isolation kit (Gentra Systems,
Minneapolis, MN). DNA extraction from four formalin-
fixed, paraffin-embedded samples was performed by
standard detergent-proteinase K lysis, followed by phe-
nol/chloroform extraction and ethanol precipitation, as
described elsewhere.22 Only tumors with .80% tumor
cell content were included in this study.
CGH and Digital Image Analysis
CGH was performed as described.22 In brief, 1 mg of
tumor DNA was labeled with Spectrum Green-dUTPs
(Vysis, Downers Grove, IL) by nick translation (BioNick
kit; Life Technologies, Basel, Switzerland). The hybridiza-
tion mixture consisted of 200 ng of Spectrum Green-
labeled tumor DNA, 200 ng of Spectrum Red-labeled
sex-matched normal reference DNA (Vysis), and 10 to 20
mg human Cot-1 DNA (Life Technologies) dissolved in 10
ml of hybridization buffer (50% formamide, 10% dextran
sulfate, 23 standard saline citrate, pH 7.0). Hybridization
to normal metaphase spreads (Vysis) took place for 3
days at 37°C. Slides were washed at 45°C three times for
10 minutes in 50% formamide/23 standard saline citrate
and two times in 23 standard saline citrate. The chromo-
somes were counterstained with 4,6-diamidino-2-phe-
nylindole in anti-fade solution for identification.
Table 1. Clinical Characteristics and Genetic Findings in Parasympathetic Paragangliomas
Patient
Age of
onset/sex Location
Size
(cm)
Horm.
activity Type
Follow-up data
(months)
LOH results
CGH resultsD11S134 D11S1986
1 33/F VAG 4.0 2 spor. NED (85) h h 5p2, 11p2
2 32/M CAR 2.5 2 fam. MUL (85) n n 11pq2
3 30/F CAR nk 2 fam. MUL (80) ni n n
4 45/F CAR 3.0 2 spor. MUL (68) ni h n
5 45/M TYMP 0.5 2 spor. NED (66) — — 11pq2
6 42/F IUG 1.5 2 spor. REC (127) — — n
7 31/F CAR 1.5 2 spor. NED (63) — — 9p2, 11pq2
8 29/F CAR 4.0 2 fam. MUL (63) ni n 1p2, 11pq2
CAR 1.8 2 ni n 11pq2, 13q2, 17pq1
9 33/M CAR 1.5 2 spor. MUL (61) h h n
CAR 2.0 2 h h n
10 39/M CAR 4.0 2 fam. MUL (56) ni h n
11 30/F CAR 3.5 2 fam. MUL (248) n n 3q2, 11q2
12 33/F TRACH 2.0 2 spor. NED (96) h h 3pq2
13 55/F AO-PULM 1.2 1 spor. NED (96) h h 5p2, 11p2
14 38/M AO-PULM 4.0 1 fam. MUL* (120) n n 2pq2, 11pq2, 18q2
Abbreviations: F, female; M, male; VAG, vagal; CAR, carotid body; TYMP, tympanic; IUG, iugular; TRACH, tracheal; AO-PULM, aorto-pulmonal; nk,
not known; fam., familial; spor., sporadic; NED, no evidence of disease; REC, local recurrence; MUL, one or more parasympathetic PGL in other
locations including the contralateral carotid body; ni, noninformative; n, no detectable changes; —, no data.
*This patient also presented with carotid body PGL and abdominal masses suggestive of paraganglioma, as detected by computed tomography
imaging.
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Digital images were collected from six to seven met-
aphases using a Photometrics cooled charge-coupled
device camera (Microimager 1400; Xillix Technologies,
Vancouver, Canada). The QUIPS software program (Vy-
sis) was used to calculate average green-to-red ratio
profiles of at least four observations per autosome and
two observations per sex chromosome in each analysis.
Gains and losses of DNA sequences were defined as
chromosomal regions where the mean green-to-red fluo-
rescence ratio was .1.20 and ,0.80, respectively. Over-
representations were considered amplifications when the
fluorescence ratio values in a subregion of a chromo-
somal arm exceeded 1.5. Because of some false-positive
results at chromosomes 1p32-pter, 16p, 19, and 22 found
in normal tissues, gains of these known G-C-rich regions
were excluded from all analyses.
LOH Analysis
To validate CGH data independently, 12 PGLs of 11
patients of whom normal DNA was available, were ana-
lyzed for allelic imbalances of the 11q23 locus using two
microsatellite markers D11S1347 and D11S1986 (Re-
search Genetics, Huntsville, AL).19 Polymerase chain re-
action amplification of tumor and germline DNA was per-
formed in reaction mixtures of 50 ml. Each reaction
contained 50 to 100 ng of template DNA, 0.2 mmol/L
dATP, dTTP, dGTP, dCTP, 20 to 50 pmol of each primer,
1.5 mmol/L Mg21, 10 mmol/L Tris-HCl, 50 mmol/L KCl,
and 1 U Taq DNA polymerase (Amplitaq Gold; Perkin
Elmer, Norwalk, CT). An initial denaturation step at 94°C
for 5 minutes was followed by 35 cycles of denaturation at
94°C for 45 seconds, annealing at 55°C (for marker
D11S1986 at 52°C) for 60 seconds, and extension at
72°C for 60 seconds. A final extension step was per-
formed at 72°C for 10 minutes. Polymerase chain reaction
products of tumor and normal DNA from each patient
were diluted 1:1 in 10 ml of loading buffer (95% form-
amide, 20 mmol/L ethylenediaminetetraacetic acid,
0.05% xylene cyanol, 0.05% bromophenol blue) and
loaded onto a nondenaturing 6% polyacrylamide gel.
Electrophoresis was performed at 40 W for 2.5 hours. The
DNA was visualized by silver staining and evaluated as
described previously.23 Allelic loss was considered to be
present when the intensity of the signal from one allele
was significantly reduced in the tumor DNA when com-
pared with normal DNA by direct visualization. Because
PGLs are known to contain admixed normal tissue (sus-
tentacular cells and supportive fibrovascular stroma), a
weak band of the lost allele was accepted in the deter-
mination of LOH.
Statistical Analysis
The chi-square test for nominal variance was used to
calculate the statistical significance of differences in
genomic changes between familial and sporadic tumors.
Results
Overview of CGH Findings
Figure 1A summarizes all DNA copy number changes
identified in 16 parasympathetic PGLs. Genetic alter-
ations were observed in 10 (63%) of 16 PGLs, and the
average number of chromosome arm aberrations per
tumor was 1.75 6 1.69 (range, 0 to 5). With the exception
of one gain of chromosome 17, all aberrations implied
chromosomal losses and no amplifications were identi-
fied (Table 1). The most common chromosome arm copy
number change was loss of chromosome 11. Six tumors
showed loss of the entire chromosome, one tumor exhib-
ited loss of 11q, and two tumors had a deletion of 11p.
Losses of chromosome 11q were strongly associated
with familial PGL (86% versus 22% in sporadic PGL) and
seemed to be statistically significant (P 5 0.012). Other
genomic imbalances were rare; one gain was found on
chromosome 17 (1 of 16), and losses involved 3q and 5p
(both 2 of 16), 1p, 3p, 9p, 13q, and 18q (1 of 16 each).
Both tumors with loss of 11p also exhibited loss of 5p and
seemed to be sporadic tumors. Representative examples
of CGH results are shown in Figure 1B.
Comparison of CGH and LOH Results
Twelve tumors of 11 patients of whom normal DNA was
available were examined by microsatellite analysis. We
could confirm the CGH results of chromosome 11q in all
tumors that were analyzed and detected LOH of this
region in one additional tumor without apparent loss of
11q in CGH analysis (Table 1). Altogether, most deletions
of chromosome 11q were found in familial PGLs (6 of 7
familial PGLs versus 2 of 9 sporadic PGLs). Representa-
tive examples of LOH results are shown in Figure 1C.
Discussion
This study represents the first comprehensive, genome-
wide analysis of chromosomal aberrations in sporadic
and familial parasympathetic PGLs. Our results indicate
that DNA copy number changes are infrequent in these
tumors and that tumor suppressor genes on chromosome
11 may play a critical role in the tumorigenesis of familial
PGLs. Sporadic PGLs may develop along different ge-
netic pathways.
Cancer, as a genetic disease, is believed to arise from
an accumulation of genetic aberrations that promote
clonal selection of cells with increasingly aggressive be-
havior. It is proposed that most cancer cell genotypes
demonstrate essential alterations in cell physiology. This
is reflected by the finding of multiple chromosomal im-
balances in the majority of human cancers. However, our
results indicate that DNA copy number changes are in-
frequent in parasympathetic PGLs. This is consistent with
their characteristically slow growth rate and benign be-
havior and indicates that some cell-signaling mecha-
nisms, generally disrupted in cancer cells, may still be
intact in PGL tumor cells.
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Figure 1. A: Summary of all DNA copy number changes detected by CGH in 16 (seven familial and nine sporadic) parasympathetic PGLs. The vertical green lines
on the right side of the chromosome ideograms indicate gains, the red lines on the left side indicate losses of the corresponding chromosomal region. Findings
in sporadic PGLs are indicated as solid bars. B: Individual examples of CGH digital images (left) and fluorescent ratio profiles (right) illustrating genomic
alterations of chromosome 3 (loss), 5 (loss of 5p), 11 (loss of the entire chromosome and of 11p), and 17 (gain). C: Example of LOH analysis of a familial PGL,
showing a band markedly diminished in tumoral (T) DNA in comparison with normal (N) DNA (allelic loss) in two microsatellite markers at 11q23, D11S1986,
and D11S1347 (red arrowheads).
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In a considerable proportion of PGLs, we found a
normal DNA copy number profile. To exclude the possi-
bility of false-negative results, we included in our analysis
only samples with at least .80% tumor cells. Nonethe-
less, it should be borne in mind that the lower limit of
CGH-based detection is ;10 Mb. Indeed, we found ad-
ditional loss of 11q by LOH analysis in one tumor.
Only one PGL in this study showed a DNA copy num-
ber gain. This gain could not be related to one of the
proteins found to be up-regulated in PGLs.13–15 There-
fore, in parasympathetic PGL, up-regulation of growth
stimulating factors is probably caused by other events,
such as genetic mutations or rearrangements.
Loss of 11q was the most common chromosomal ab-
erration in our series of PGLs, with a remarkable differ-
ence in incidence between familial and sporadic tumors
(86% versus 22%, respectively; P 5 0.012). This may
point toward distinct tumorigenic pathways in these sub-
groups of PGLs.
Co-occurrence of parasympathetic PGLs and sympa-
thoadrenal PGLs (including PCCs) has been de-
scribed.6,8 Because these tumors share many histologi-
cal characteristics, they may be thought to result from
similar genetic changes. However, comparison of CGH
data of benign parasympathetic and sympathoadrenal
PGLs shows that these types are genetically different. In
benign sympathoadrenal PGLs, genetic changes are
much more frequent and 11q losses are less frequent
compared to the parasympathetic PGLs in this study.24,25
Yet, it remains to be tested whether the same tumor
suppressor gene(s) on 11q are involved in the tumorigen-
esis of both parasympathetic PGLs and PCCs.
The long arm of chromosome 11 contains two well-
defined critical regions that each harbor a putative PGL
disease gene, PGL1 at 11q23 and PGL2 at 11q13.16,18,26
Recently, Baysal and co-workers27 detected germline
mutations of the mitochondrial succinate dehydrogenase
complex II subunit d (SDHD) gene (11q23) co-segregat-
ing with tumor occurrence in PGL families, indicating that
this is the putative PGL1 gene. The mitochondrial com-
plex II is an important enzyme complex in the aerobic
respiratory chains of mitochondria. Loss of function of this
complex may cause cellular hypoxia and increased su-
peroxide levels. Chronic hypoxia is known to be an im-
portant cause of carotid body hyperplasia and conceiv-
ably plays a role in tumor initiation and progression of
carotid body PGLs. In this respect, it is of interest that two
of nine sporadic PGLs showed loss of 5p, the gene locus
of another component (the flavoprotein subunit) of the
mitochondrial succinate dehydrogenase complex II.28
These tumors also demonstrated loss of 11p, but not of
11q. This may imply that in the pathogenesis of some
sporadic PGLs, other components of the mitochondrial
complex II are involved in their tumorigenesis.
In conclusion, our study demonstrates that chromo-
somal imbalances are infrequent in parasympathetic
PGLs compared to their sympathetic counterpart, PCCs.
We observed a high frequency of 11q loss in familial but
not in sporadic PGLs, pointing toward differences in the
genetic evolution of familial and sporadic PGLs. Genetic
changes on chromosome 11p and 5p may be involved in
sporadic PGLs.
More genetic data are needed to assess the concept
and aspects of genetic differences between familial and
sporadic parasympathetic PGLs. Further analysis of the
candidate tumor suppressor gene SDHD and other
genes of the mitochondrial complex II is required to de-
termine their involvement in the development of these
tumors.
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